Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Retrospective analysis of gastric cancer management in a real-world setting: a single-institution experience.

Monti M, Massa I, Foca F, Morgagni P, Framarini M, Passardi A, Falcini F, Frassineti GL.

Tumori. 2020 Mar 13:300891620910488. doi: 10.1177/0300891620910488. [Epub ahead of print]

PMID:
32167020
2.

Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial.

Barni S, Rosati G, Lonardi S, Pella N, Banzi M, Zampino MG, Dotti KF, Rimassa L, Marchetti P, Maiello E, Artioli F, Ferrari D, Labianca R, Bidoli P, Zaniboni A, Sobrero A, Iaffaioli V, De Placido S, Frassineti GL, Ciarlo A, Buonadonna A, Silvestris N, Piazza E, Pavesi L, Moroni M, Clerico M, Aglietta M, Giordani P, Galli F, Galli F, Petrelli F.

Ther Adv Med Oncol. 2020 Jan 20;12:1758835919899850. doi: 10.1177/1758835919899850. eCollection 2020.

3.

1H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages.

Casadei-Gardini A, Del Coco L, Marisi G, Conti F, Rovesti G, Ulivi P, Canale M, Frassineti GL, Foschi FG, Longo S, Fanizzi FP, Giudetti AM.

Cancers (Basel). 2020 Jan 18;12(1). pii: E241. doi: 10.3390/cancers12010241.

4.

Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers 2019, 11, 663.

Passardi A, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Gardini A, Barba G, Pagan F, Casadei-Gardini A, Valgiusti M, Ferroni F, Frassineti GL, Romeo A.

Cancers (Basel). 2020 Jan 10;12(1). pii: E178. doi: 10.3390/cancers12010178.

5.

Microbiological evaluation of environmental cleanliness in haematopoietic cell transplant patient rooms: implementing JACIE standards.

Zeneli A, Petrini M, Foca F, Bernabini M, Ronconi S, Montalti S, Pancisi E, Soldati V, Golinucci M, Frassineti GL, Altini M.

J Hosp Infect. 2020 Mar;104(3):276-282. doi: 10.1016/j.jhin.2019.11.016. Epub 2019 Nov 28.

PMID:
31785318
6.

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study.

Casadei-Gardini A, Scarpi E, Ulivi P, Palladino MA, Accettura C, Bernardini I, Spallanzani A, Gelsomino F, Corbelli J, Marisi G, Ruscelli S, Valgiusti M, Frassineti GL, Passardi A.

Cancer Manag Res. 2019 May 10;11:4357-4369. doi: 10.2147/CMAR.S198651. eCollection 2019. Erratum in: Cancer Manag Res. 2020 Jan 23;12:541.

7.

Preoperative Chemotherapy and Resection Margin Status in Colorectal Liver Metastasis Patients: A Propensity Score-Matched Analysis.

Solaini L, Gardini A, Passardi A, Mirarchi MT, D'Acapito F, La Barba G, Cucchi M, Casadei Gardini A, Frassineti GL, Cucchetti A, Ercolani G.

Am Surg. 2019 May 1;85(5):488-493.

PMID:
31126361
8.

Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study.

Passardi A, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Gardini A, La Barba G, Pagan F, Casadei-Gardini A, Valgiusti M, Ferroni F, Frassineti GL, Romeo A.

Cancers (Basel). 2019 May 13;11(5). pii: E663. doi: 10.3390/cancers11050663. Erratum in: Cancers (Basel). 2020 Jan 10;12(1):.

9.

Aeromonas veronii biovar veronii and sepsis-infrequent complication of biliary drainage placement: A case report.

Monti M, Torri A, Amadori E, Rossi A, Bartolini G, Casadei C, Frassineti GL.

World J Clin Cases. 2019 Mar 26;7(6):759-764. doi: 10.12998/wjcc.v7.i6.759.

10.

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F.

BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

11.

Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study.

Solaini L, D'Acapito F, Passardi A, Framarini M, Tauceri F, Di Pietrantonio D, Frassineti GL, Casadei Gardini A, Cucchetti A, Cavaliere D, Ercolani G.

World J Surg Oncol. 2019 Mar 27;17(1):58. doi: 10.1186/s12957-019-1602-z.

12.

Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.

De Matteis S, Scarpi E, Granato AM, Vespasiani-Gentilucci U, La Barba G, Foschi FG, Bandini E, Ghetti M, Marisi G, Cravero P, Gramantieri L, Cucchetti A, Ercolani G, Santini D, Frassineti GL, Faloppi L, Scartozzi M, Cascinu S, Casadei-Gardini A.

Int J Mol Sci. 2019 Mar 26;20(6). pii: E1503. doi: 10.3390/ijms20061503.

13.

Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.

Vernieri C, Galli F, Ferrari L, Marchetti P, Lonardi S, Maiello E, Iaffaioli RV, Zampino MG, Zaniboni A, De Placido S, Banzi M, Damiani A, Ferrari D, Rosati G, Labianca RF, Bidoli P, Frassineti GL, Nicolini M, Pavesi L, Tronconi MC, Buonadonna A, Ferrario S, Re GL, Adamo V, Tamburini E, Clerico M, Giordani P, Leonardi F, Barni S, Ciarlo A, Cavanna L, Gori S, Cinieri S, Faedi M, Aglietta M, Antista M, Dotti KF, Galli F, Di Bartolomeo M; TOSCA (Three or Six Colon Adjuvant) Investigators.

Oncologist. 2019 Mar;24(3):385-393. doi: 10.1634/theoncologist.2018-0442. Epub 2019 Jan 3.

14.

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab.

Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P.

Cancer Manag Res. 2018 Nov 14;10:5659-5666. doi: 10.2147/CMAR.S181570. eCollection 2018.

15.

Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib.

Casadei Gardini A, Scarpi E, Foschi FG, Marisi G, Maltoni M, Frassineti GL.

Clin Res Hepatol Gastroenterol. 2019 Oct;43(5):e76-e78. doi: 10.1016/j.clinre.2018.11.005. Epub 2018 Dec 5. No abstract available.

PMID:
30528062
16.

Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials.

Casadei Gardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, Sangro B.

Onco Targets Ther. 2018 Oct 25;11:7315-7321. doi: 10.2147/OTT.S175715. eCollection 2018.

17.

Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival.

Casadei Gardini A, Marisi G, Canale M, Foschi FG, Donati G, Ercolani G, Valgiusti M, Passardi A, Frassineti GL, Scarpi E.

Onco Targets Ther. 2018 Oct 5;11:6555-6567. doi: 10.2147/OTT.S170836. eCollection 2018.

18.

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A.

World J Gastroenterol. 2018 Sep 28;24(36):4152-4163. doi: 10.3748/wjg.v24.i36.4152. Review.

19.

Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial.

Casadei Gardini A, Scarpi E, Orlandi E, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Ruscelli S, Vespignani R, Ronconi S, Frassineti GL, Amadori D, Passardi A.

Onco Targets Ther. 2018 Aug 29;11:5261-5268. doi: 10.2147/OTT.S166614. eCollection 2018.

20.

Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma.

Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G, Scartozzi M, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G, Frassineti GL, Casadei Gardini A.

Crit Rev Oncol Hematol. 2018 Sep;129:44-53. doi: 10.1016/j.critrevonc.2018.06.017. Epub 2018 Jun 23. Review.

PMID:
30097237
21.

Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis.

Mori G, Rampelli S, Orena BS, Rengucci C, De Maio G, Barbieri G, Passardi A, Casadei Gardini A, Frassineti GL, Gaiarsa S, Albertini AM, Ranzani GN, Calistri D, Pasca MR.

Sci Rep. 2018 Jul 9;8(1):10329. doi: 10.1038/s41598-018-28671-9.

22.

Chemotherapy and palliative care near end-of life: examining the appropriateness at a cancer institute for colorectal cancer patients.

Massa I, Nanni O, Foca F, Maltoni M, Derni S, Gentili N, Frassineti GL, Casadei Gardini A, Valgiusti M, Amadori D, Prati E, Altini M, Gallegati D, Sansoni E.

BMC Palliat Care. 2018 Jun 19;17(1):86. doi: 10.1186/s12904-018-0339-8.

23.

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.

Cremolini C, Rossini D, Martinelli E, Pietrantonio F, Lonardi S, Noventa S, Tamburini E, Frassineti GL, Mosconi S, Nichetti F, Murgioni S, Troiani T, Borelli B, Zucchelli G, Dal Maso A, Sforza V, Masi G, Antoniotti C, Di Bartolomeo M, Miceli R, Ciardiello F, Falcone A.

Oncologist. 2018 Oct;23(10):1178-1187. doi: 10.1634/theoncologist.2017-0573. Epub 2018 May 8.

24.

Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.

Gardini AC, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J, Chessa L, Bruno D, Ercolani G, Leonetti A, Stefano G, Farella N, Foschi FG, Lanzi A, Dadduzio V, Marisi G, Masi G, Negri FV, Pagan F, Santini D, Scarpi E, Silletta M, Silvestris N, Tamburini E, Tassinari D, Vivaldi C, Gentilucci UV, Zagonel V, Calvetti L, Cascinu S, Frassineti GL, Scartozzi M.

Tumori. 2018 Dec;104(6):476-479. doi: 10.5301/tj.5000704. Epub 2018 May 9.

PMID:
29739298
25.

Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.

Pastorino A, Di Bartolomeo M, Maiello E, Iaffaioli V, Ciuffreda L, Fasola G, Di Costanzo F, Frassineti GL, Marchetti P, Antoniotti C, Leone F, Zaniboni A, Aprile G, Zilocchi C, Sobrero A, Bordonaro R.

Clin Colorectal Cancer. 2018 Sep;17(3):e457-e470. doi: 10.1016/j.clcc.2018.03.002. Epub 2018 Mar 8.

26.

Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy.

Casadei Gardini A, Passardi A, Fornaro L, Rosetti P, Valgiusti M, Ruscelli S, Monti M, Casadei C, Pagan F, Frassineti GL.

Crit Rev Oncol Hematol. 2018 Mar;123:52-56. doi: 10.1016/j.critrevonc.2018.01.007. Epub 2018 Feb 2. Review.

PMID:
29482779
27.

Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.

Amadori M, Barone D, Scarpi E, Oboldi D, Amadori E, Bandi G, Rossi A, Ferroni F, Ragazzini A, Casadei Gardini A, Frassineti GL, Gavelli G, Passardi A.

Eur Radiol. 2018 Jul;28(7):2969-2978. doi: 10.1007/s00330-017-5254-5. Epub 2018 Feb 7.

PMID:
29417252
28.

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.

Ulivi P, Canale M, Passardi A, Marisi G, Valgiusti M, Frassineti GL, Calistri D, Amadori D, Scarpi E.

Int J Mol Sci. 2018 Jan 20;19(1). pii: E307. doi: 10.3390/ijms19010307.

29.

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review.

Casadei Gardini A, Santini D, Aprile G, Silvestris N, Felli E, Foschi FG, Ercolani G, Marisi G, Valgiusti M, Passardi A, Puzzoni M, Silletta M, Brunetti O, Cardellino GG, Frassineti GL, Scartozzi M.

Oncotarget. 2017 Jul 22;8(39):66699-66708. doi: 10.18632/oncotarget.19449. eCollection 2017 Sep 12. Review.

30.

Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.

Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G, Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi A, Santini D, Cascinu S, Frassineti GL, Scartozzi M.

Eur J Cancer. 2017 Nov;86:106-114. doi: 10.1016/j.ejca.2017.09.003. Epub 2017 Oct 3.

PMID:
28985579
31.

Bordetella bronchiseptica pneumonia in a patient with lung cancer; a case report of a rare infection.

Monti M, Diano D, Allegrini F, Delmonte A, Fausti V, Cravero P, Marcantognini G, Frassineti GL.

BMC Infect Dis. 2017 Sep 25;17(1):644. doi: 10.1186/s12879-017-2736-7.

32.

Treatment of squamous cell carcinoma of the anal canal (SCCA): a new era?

Casadei Gardini A, Valgiusti M, Passardi A, Frassineti GL.

Ann Oncol. 2017 Oct 1;28(10):2620. doi: 10.1093/annonc/mdx291. No abstract available.

33.

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.

Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M, Ulivi P, Amadori D.

Sci Rep. 2017 Sep 5;7(1):10426. doi: 10.1038/s41598-017-11048-9.

34.

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.

Ulivi P, Scarpi E, Chiadini E, Marisi G, Valgiusti M, Capelli L, Casadei Gardini A, Monti M, Ruscelli S, Frassineti GL, Calistri D, Amadori D, Passardi A.

Int J Mol Sci. 2017 Jun 9;18(6). pii: E1240. doi: 10.3390/ijms18061240.

35.

Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials.

Casadei Gardini A, Frassineti GL, Foschi FG, Ercolani G, Ulivi P.

Dig Liver Dis. 2017 Aug;49(8):943-944. doi: 10.1016/j.dld.2017.04.022. Epub 2017 May 6. No abstract available.

PMID:
28546063
36.

Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma.

De Matteis S, Granato AM, Napolitano R, Molinari C, Valgiusti M, Santini D, Foschi FG, Ercolani G, Vespasiani Gentilucci U, Faloppi L, Scartozzi M, Frassineti GL, Casadei Gardini A.

Dig Dis Sci. 2017 Aug;62(8):1872-1880. doi: 10.1007/s10620-017-4615-x. Epub 2017 May 19. Review.

PMID:
28527050
37.

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.

Marisi G, Scarpi E, Passardi A, Nanni O, Ragazzini A, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P.

Sci Rep. 2017 May 2;7(1):1293. doi: 10.1038/s41598-017-01420-0.

38.

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study.

Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi L, Brunetti O, Rudnas B, Pisconti S, Valgiusti M, Marisi G, Foschi FG, Ercolani G, Tassinari D, Cascinu S, Frassineti GL.

Sci Rep. 2017 Feb 13;7:42499. doi: 10.1038/srep42499.

39.

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.

Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang DZ, Kim G, Stella P, Richel D, Szcylik C, Cascinu S, Frassineti GL, Ciuleanu T, Hurt K, Hynes S, Lin J, Lin AB, Von Hoff D, Calvo E.

BMC Cancer. 2017 Feb 15;17(1):137. doi: 10.1186/s12885-017-3131-x.

40.

Erratum to "Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life" [Eur J Cancer 69 (2016) 110-118].

Maltoni M, Scarpi E, Dall'Agata M, Schiavon S, Biasini C, Codecà C, Broglia CM, Sansoni E, Bortolussi R, Garetto F, Fioretto L, Cattaneo MT, Giacobino A, Luzzani M, Luchena G, Alquati S, Quadrini S, Zagonel V, Cavanna L, Ferrari D, Pedrazzoli P, Frassineti GL, Galiano A, Casadei Gardini A, Monti M, Nanni O; Early Palliative Care Italian Study Group (EPCISG).

Eur J Cancer. 2017 Feb;72:272-273. doi: 10.1016/j.ejca.2016.11.024. Epub 2016 Dec 24. No abstract available.

PMID:
28027830
41.

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).

Capelli L, Casadei Gardini A, Scarpi E, Frassineti GL, Saragoni L, Puccetti M, Scartozzi M, Giannini M, Tamberi S, Corbelli J, Ulivi P.

Sci Rep. 2016 Nov 25;6:37621. doi: 10.1038/srep37621.

42.

Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life.

Maltoni M, Scarpi E, Dall'Agata M, Schiavon S, Biasini C, Codecà C, Broglia CM, Sansoni E, Bortolussi R, Garetto F, Fioretto L, Cattaneo MT, Giacobino A, Luzzani M, Luchena G, Alquati S, Quadrini S, Zagonel V, Cavanna L, Ferrari D, Pedrazzoli P, Frassineti GL, Galiano A, Casadei Gardini A, Monti M, Nanni O; Early Palliative Care Italian Study Group (EPCISG).

Eur J Cancer. 2016 Dec;69:110-118. doi: 10.1016/j.ejca.2016.10.004. Epub 2016 Nov 4. Erratum in: Eur J Cancer. 2017 Feb;72 :272-273.

PMID:
27821313
43.

Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions.

Casadei Gardini A, Tenti E, Masini C, Nanni O, Scarpi E, Valgiusti M, Restuccia S, Gallani ML, Palazzini S, Bianchini E, Menozzi S, Maugeri A, Amadori D, Minguzzi M, Frassineti GL.

Oncotarget. 2016 Jun 28;7(26):40719-40724. doi: 10.18632/oncotarget.8942.

44.

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.

Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, de Stefano G, Marisi G, Negri FV, Foschi FG, Valgiusti M, Ercolani G, Frassineti GL.

Oncotarget. 2016 Oct 11;7(41):67142-67149. doi: 10.18632/oncotarget.11565.

45.

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.

Casadei Gardini A, Chiadini E, Faloppi L, Marisi G, Delmonte A, Scartozzi M, Loretelli C, Lucchesi A, Oboldi D, Dubini A, Frassineti GL, Ulivi P.

BMC Cancer. 2016 Jul 7;16:429. doi: 10.1186/s12885-016-2463-2.

46.

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer.

Passardi A, Scarpi E, Cavanna L, Dall'Agata M, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Brandes AA, Tenti E, Vespignani R, Frassineti GL, Amadori D, De Giorgi U.

Oncotarget. 2016 May 31;7(22):33210-9. doi: 10.18632/oncotarget.8901.

47.

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.

Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M, Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Della Corte C, Neri LM, Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti E, Ulivi P, Frassineti GL.

Oncotarget. 2016 May 10;7(19):27988-99. doi: 10.18632/oncotarget.8569.

48.

Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.

Casadei Gardini A, Scarpi E, Marisi G, Foschi FG, Donati G, Giampalma E, Faloppi L, Scartozzi M, Silvestris N, Bisulli M, Corbelli J, Gardini A, La Barba G, Veneroni L, Tamberi S, Cascinu S, Frassineti GL.

Oncotarget. 2016 Mar 22;7(12):15243-51. doi: 10.18632/oncotarget.7444.

49.

Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report.

Casadei Gardini A, Mariotti M, Lucchesi A, Pini S, Valgiusti M, Bravaccini S, Del Monte A, Burgio MA, Marisi G, Amadori D, Frassineti GL.

BMC Cancer. 2016 Feb 17;16:118. doi: 10.1186/s12885-016-2167-7.

50.

Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study.

Massa I, Nanni O, Guidoboni M, Frassineti GL, Rocca A, Burgio MA, Valmorri L, Marri M, Piancastelli A, Faedi M, Leoni M, Tamberi S, Altini M, Amadori D.

Oncol Lett. 2016 Jan;11(1):831-836. Epub 2015 Nov 24.

Supplemental Content

Loading ...
Support Center